BICX
BIOCORRX INC NEW
Latest price
As of Oct 30, 2026, 9:31 AM EDT · Market data by Massive
Market cap
—
Volume
184
Previous close
$0.2500
Day range
$0.2010 – $0.2010
Listed
—
Coverage
20 articles
Price performance
Recent trading
Newsroom
Latest BICX coverage
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
[ad_1] ANAHEIM, CA – (NewMediaWire) – February 28, 2024 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc. has been awarded a 3-year grant for approximately $11 million from the National
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
[ad_1] ANAHEIM, CA – (NewMediaWire) – February 8, 2024 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors. Dr. DeVarn
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
[ad_1] ANAHEIM, CA – (NewMediaWire) – January 09, 2024 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced the appointment of Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and he will
BioCorRx Reports Business Update for the Third Quarter of 2023
[ad_1] ANAHEIM, CA – (NewMediaWire) – November 14, 2023 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and reported on recent corporate developments. Lourdes F
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
[ad_1] Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis ANAHEIM, CA – (NewMediaWire) – August 15, 2023 – BioCorRx Inc. (OTCQB: BICX) (the “Company”) today announced its submission to the US Food and Drug Administration (FDA) of an expanded access program application for
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
[ad_1] · BICX104 was Well Tolerated with No Serious Adverse Events Reported and Achieved 84 Days of Therapeutic Naltrexone Plasma Concentrations · BICX104 Subjects Experienced Better 84-Day Treatment Adherence Than Vivitrol® Subjects · Company Seeking FDA Approval for Immediate Expanded Access “Compassionate Use” of BICX104 for Over 10 Milli
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
[ad_1] Presentation on Thursday, February 2, 2023 at 2:00 PM ET ANAHEIM, CA – (NewMediaWire) – January 27, 2023 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Lourdes Felix, Chief Executive Officer, Chief Financial Officer
BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.
[ad_1] Anaheim, CA – (NewMediaWire) – November 22, 2022 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that its board of directors has authorized the exploration of a potential spin-off of BioCorRx Pharmaceuticals, Inc., the
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
[ad_1] ANAHEIM, CA – (NewMediaWire) – June 30, 2022 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the first subject has been dosed in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet
BioCorRx Featured on LiveNOW from FOX
[ad_1] ANAHEIM, CA – (NewMediaWire) – June 17, 2022 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Tom Welch, Executive Vice President of BioCorRx Inc., was featured on LiveNOW from FOX. Mr. Welch discussed BioCorRx’s pi
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting
[ad_1] Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual reality technology Plans toward expanding the offering to other at-risk groups upon evaluating results of pilot with veterans ANAHEIM, CA – (NewMediaWire) – May 19, 2022 – BioCorRx Inc. (OTCQB: BICX) (the “Company”),
BioCorRx Provides 2021 Year-End Business Update
[ad_1] ANAHEIM, CA – (NewMediaWire) – April 01, 2022 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a year-end business update for 2021 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of B
BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder
[ad_1] ANAHEIM, CA – (NewMediaWire) – March 16, 2022 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced it has received Independent Institutional Review Board (IRB) approval for the Company’s Phase I clinical trial of BICX104, an
BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board
[ad_1] ANAHEIM, CA – (NewMediaWire) – December 09, 2021 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the appointment of Dr. Jie Shen to the Scientific Advisory Board (SAB). Dr. Jie Shen is an Assistant Professor in the Depa
BioCorRx to Participate in the Benzinga All Access Event on December 2nd
[ad_1] ANAHEIM, CA – (NewMediaWire) – November 24, 2021 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioCorRx, Inc. and Brady Granier, President and Director, CEO of BioCorRx Pha
BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th
[ad_1] Anaheim, CA – (NewMediaWire) – September 29, 2021 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it will be presenting at LD Micro’s 14th annual Main Event on Tuesday, October 12, 2021, at 1:30 PM PT/4:30 PM ET ...
BioCorRx Provides 2020 Year-End Business Update
[ad_1] Anaheim, CA – (NewMediaWire) – April 01, 2021 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2020 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc
BioCorRx Announces Update on NIDA Grant and Development of Naltrexone Implant for the Treatment of Opioid and Alcohol Use Disorders
[ad_1] Anaheim, CA – (NewMediaWire) – January 15, 2021 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it has received a revised notice of award (NoA) to extend the current UG3 phase of the grant awardedby the National Institute o
BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study
[ad_1] Announces Promotion of Lourdes Felix to CEO; Brady Granier to Serve as President Anaheim, CA – (NewMediaWire) – November 16, 2020 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the third quarter ended Septe
BioCorRx Provides Business Update for the Second Quarter of 2020
[ad_1] Anaheim, CA – (NewMediaWire) – August 14, 2020 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2020. Brady Granier, CEO, and Director of BioCorRx, Inc., stated, “Despite th